X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
FDA Allows IND to study ATI-450 in hospitalized patients with COVID-19. Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug supply.
Lead Product(s): ATI-450
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-450
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
Abstract highlights data from a Phase 1 study in healthy volunteers exploring the safety, pharmacokinetics and pharmacodynamics of ATI-450, a novel oral MK2 inhibitor.
Lead Product(s): ATI-450,Methotrexate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
ATI-450 resulted in inhibition of TNF?, IL1?, IL8, and IL6, was generally well-tolerated at all doses tested in the trial; had no significant food effect or drug-drug interaction with methotrexate.
Lead Product(s): ATI-450,Methotrexate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
